Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ADA
Biotech
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2
With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market.
Eric Sagonowsky
Jun 9, 2026 9:48am
Fierce Pharma
Eli Lilly is the ‘clear winner’ from ADA, RBC analyst says
Jun 8, 2026 3:12pm
ADA: Tandem takes aim at late adopters of diabetes tech
Jun 28, 2023 9:00am
ADA: Dexcom plots 2024 launch of sensor for non-insulin users
Jun 27, 2023 1:27pm
Abbott inks collabs to bring CGM tech to Type 2 diabetes
Jun 25, 2023 6:56pm
ADA: Medtronic touts MiniMed 780G wins for kids with diabetes
Jun 24, 2023 7:06pm
